PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer

Table 1

The relationship between PCMT1 and the clinicopathological parameters of breast cancer (bc-GenExMiner v4.7).

Clinical parameters	PCMT1
	No.	value
Age
≤ 51	2947	<0.0001
> 51	4796
Nodal status
Negative	4408	0.1226
Positive	3717
ER (IHC)
Negative	2606	0.6540
Positive	7210
PR (IHC)
Negative	2727	0.0042
Positive	3483
HER2(IHC)
Negative	4768	0.0294
Positive	794
Triple-negative status
Not	7744	0.2142
TNBC	940
P53 status (IHC)
Wild type	638	0.0001
Mutated	284

All the data of the PCMT1 were based on bc-GenExMiner v4.7. “No.” means the patients’ number from database; “” means higher mRNA expression level compared with the same group. ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; TNBC: triple-negative breast cancer. The data with statistical significance () were marked in bold text.